Neurocrine Biosciences
NBIX
#1532
Rank
C$16.26 B
Marketcap
$163.11
Share price
-1.58%
Change (1 day)
-9.60%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $2.78. In 2022 the company made an earnings per share (EPS) of $2.28 an increase over its 2021 EPS that were of $1.35.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.6315.36%
2022$2.2869.47%
2021$1.35-78.21%
2020$6.18990%
2019$0.5781.82%
2018$0.31-113.5%
2017-$2.310.62%
2016-$2.3057.28%
2015-$1.4625.61%
2014-$1.1618.84%
2013-$0.98-1085.71%
2012$0.09927-89.71%
2011$0.96-500%
2010-$0.24-86.92%
2009-$1.84-43.48%
2008-$3.26-57.8%
2007-$7.7392.58%
2006-$4.01371.67%
2005-$0.85-52.76%
2004-$1.8036.56%
2003-$1.32-70%
2002-$4.40118.31%
2001-$2.018.4%
2000-$1.8648.86%
1999-$1.25-20%
1998-$1.56-479.31%
1997$0.41

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$2.96 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.78-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.20-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.70 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.22 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.64-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.67-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.30-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA